

Antonio Lax

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/216535/publications.pdf>

Version: 2024-02-01

51
papers

12,935
citations

304368

22
h-index

189595

50
g-index

53
all docs

53
docs citations

53
times ranked

12364
citing authors

#	ARTICLE	IF	CITATIONS
1	Critical warm ischemia time point for cardiac donation after circulatory death. American Journal of Transplantation, 2022, 22, 1321-1328.	2.6	16
2	The miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI. Scientific Reports, 2021, 11, 3915.	1.6	6
3	Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status. Scientific Reports, 2020, 10, 13553.	1.6	21
4	Differences in the Interleukin-1 ^β /Soluble ST2 Interplay Between Acute and Chronic Heart Failure. Journal of Cardiovascular Translational Research, 2020, 13, 864-866.	1.1	1
5	Reply. Journal of the American College of Cardiology, 2019, 74, 479-480.	1.2	0
6	Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With and Without Diabetes. JACC Basic To Translational Science, 2019, 4, 831-840.	1.9	65
7	Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction. Journal of Molecular and Cellular Cardiology, 2019, 130, 216-233.	0.9	14
8	The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure. Journal of the American College of Cardiology, 2019, 73, 1016-1025.	1.2	52
9	Temporal characterization of cardiac expression of glucose transporters SGLT and GLUT in an experimental model of myocardial infarction. Diabetes and Metabolism, 2019, 45, 201-204.	1.4	1
10	Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKC β /Gal-3 pathway reduces left ventricular fibrosis following myocardial infarction. Translational Research, 2018, 199, 4-23.	2.2	20
11	Pulmonary Production of Soluble ST2 in Heart Failure. Circulation: Heart Failure, 2018, 11, e005488.	1.6	52
12	Noncardiac Production of Soluble ST2 in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2018, 72, 1429-1430.	1.2	9
13	Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey). American Journal of Cardiology, 2018, 122, 578-583.	0.7	12
14	Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72h in an Experimental Rat Model of Acute Myocardial Infarction. Journal of Cardiovascular Translational Research, 2017, 10, 460-469.	1.1	7
15	Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes. PLoS ONE, 2017, 12, e0172803.	1.1	96
16	Atrial Fibrillation Management in Older Heart Failure Patients: A Complex Clinical Problem. Heart International, 2016, 11, heartint.500023.	0.4	10
17	Barriers to cardiac rehabilitation access of older heart failure patients and strategies for better implementation. Monaldi Archives for Chest Disease, 2016, 84, 732.	0.3	11
18	Cardiac rehabilitation is safe and effective also in the elderly, but don't forget about drugs!. Monaldi Archives for Chest Disease, 2016, 84, 737.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Early oxidative damage induced by doxorubicin: Source of production, protection by GKT137831 and effect on Ca ²⁺ transporters in HL-1 cardiomyocytes. Archives of Biochemistry and Biophysics, 2016, 594, 26-36.	1.4	31
20	Factor de transcripci3n TBX1 en el remodelado cardiaco asociado al infarto de miocardio. Revista Espanola De Cardiologia, 2016, 69, 1042-1050.	0.6	1
21	The TBX1 Transcription Factor in Cardiac Remodeling After Myocardial Infarction. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1042-1050.	0.4	0
22	Reformulated meat products protect against ischemia-induced cardiac damage. Food and Function, 2016, 7, 992-1001.	2.1	2
23	Clinical relevance of sST2 in cardiac diseases. Clinical Chemistry and Laboratory Medicine, 2016, 54, 29-35.	1.4	57
24	Mineralocorticoid Receptor Antagonists Modulate Galectin-3 and Interleukin-33/ST2 Signaling in Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction. JACC: Heart Failure, 2015, 3, 50-58.	1.9	77
25	Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. European Journal of Clinical Investigation, 2014, 44, 643-651.	1.7	57
26	Ferritin heavy chain as main mediator of preventive effect of metformin against mitochondrial damage induced by doxorubicin in cardiomyocytes. Free Radical Biology and Medicine, 2014, 67, 19-29.	1.3	24
27	Galectin-3 expression in cardiac remodeling after myocardial infarction. International Journal of Cardiology, 2014, 172, e98-e101.	0.8	51
28	Prognostic markers for acute heart failure. Expert Opinion on Medical Diagnostics, 2013, 7, 379-392.	1.6	11
29	High sensitive cardiac troponin T in the management of uncertain chest pain. International Journal of Cardiology, 2013, 168, 4422-4423.	0.8	2
30	Involvement of ferritin heavy chain in the preventive effect of metformin against doxorubicin-induced cardiotoxicity. Free Radical Biology and Medicine, 2013, 57, 188-200.	1.3	38
31	Red blood cell distribution width predicts new-onset anemia in heart failure patients. International Journal of Cardiology, 2012, 160, 196-200.	0.8	35
32	Passive Ca ²⁺ overload in H9c2 cardiac myoblasts: Assessment of cellular damage and cytosolic Ca ²⁺ transients. Archives of Biochemistry and Biophysics, 2011, 512, 175-182.	1.4	2
33	Anabolic Status and Functional Impairment in Men With Mild Chronic Heart Failure. American Journal of Cardiology, 2011, 108, 862-866.	0.7	13
34	Metformin protects against doxorubicin-induced cardiotoxicity: Involvement of the adiponectin cardiac system. Free Radical Biology and Medicine, 2011, 51, 1861-1871.	1.3	85
35	Soluble ST2 Is a Marker for Acute Cardiac Allograft Rejection. Annals of Thoracic Surgery, 2011, 92, 2118-2124.	0.7	41
36	Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. Chest, 2010, 137, 263-272.	0.4	5,657

#	ARTICLE	IF	CITATIONS
37	Progression From Paroxysmal to Persistent Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2010, 55, 725-731.	1.2	579
38	Differential Actions of Eplerenone and Spironolactone on the Protective Effect of Testosterone Against Cardiomyocyte Apoptosis In Vitro. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 779-787.	0.4	7
39	A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. <i>Chest</i> , 2010, 138, 1093-1100.	0.4	3,810
40	Mitochondrial damage as death inducer in heart-derived H9c2 cells: more than one way for an early demise. <i>Journal of Bioenergetics and Biomembranes</i> , 2009, 41, 369-377.	1.0	7
41	Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation. <i>European Heart Journal</i> , 2008, 29, 1181-1189.	1.0	247
42	Cellular death linked to irreversible stress in the sarcoplasmic reticulum: The effect of inhibiting Ca ²⁺ -ATPase or protein glycosylation in the myocardial cell model H9c2. <i>Archives of Biochemistry and Biophysics</i> , 2007, 466, 194-202.	1.4	4
43	Gender-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe. <i>Journal of the American College of Cardiology</i> , 2007, 49, 572-577.	1.2	370
44	Cytoplasmic Ca ²⁺ signals and cellular death by apoptosis in myocardial H9c2 cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2006, 1763, 937-947.	1.9	5
45	Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. <i>European Heart Journal</i> , 2006, 27, 2969-2974.	1.0	150
46	Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. <i>European Heart Journal</i> , 2006, 27, 3018-3026.	1.0	353
47	Intracellular Ca ²⁺ Pools and Fluxes in Cardiac Muscle-Derived H9c2 Cells. <i>Journal of Bioenergetics and Biomembranes</i> , 2005, 37, 249-259.	1.0	13
48	Atrial fibrillation management: a prospective survey in ESC Member Countries. <i>European Heart Journal</i> , 2005, 26, 2422-2434.	1.0	770
49	Functional Approach to the Catalytic Site of the Sarcoplasmic Reticulum Ca ²⁺ -ATPase: Binding and Hydrolysis of ATP in the Absence of Ca ²⁺ . <i>Journal of Bioenergetics and Biomembranes</i> , 2004, 36, 265-273.	1.0	1
50	Dissecting the Hydrolytic Activities of Sarcoplasmic Reticulum ATPase in the Presence of Acetyl Phosphate. <i>Journal of Biological Chemistry</i> , 2002, 277, 38127-38132.	1.6	7
51	Inhibition of sarcoplasmic reticulum Ca ²⁺ -ATPase by miconazole. <i>American Journal of Physiology - Cell Physiology</i> , 2002, 283, C85-C92.	2.1	13